We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Oncocyte Corp
6 own
22 watching
Current Price
$2.16
$-0.03
(-1.37%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
40.15M
52-Week High
3.82000
52-Week Low
1.98000
Average Volume
0.02M
Dividend Yield
--
P/E Ratio
--
Market Capitalization40.15M52-Week High3.8200052-Week Low1.98000Average Volume0.02MDividend Yield--P/E Ratio--What does the Oncocyte Corp do?
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Read More
How much money does Oncocyte Corp make?
News & Events about Oncocyte Corp.
Globe Newswire
1 year ago
IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying DetermaIO to samples collected from the randomized Phase II AtezoTRIBE clinical trial in metastatic ...
Globe Newswire
1 year ago
IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation(Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Officer effective February 24, 2023. Since being named interim CEO in December, Riggs has successfully ...
Globe Newswire
1 year ago
Company retains 30% stake while eliminating operating expense and future development obligations Represents next step in plan to focus product strategy IRVINE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation(Nasdaq: OCX), a precision diagnostics company, today announced that it has ...
Globe Newswire
2years ago
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation(Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocytes workforce to realign its team towards key products that address larger markets. Additionally, Oncocyte has ...
Zolmax
2years ago
OncoCyte (NASDAQ:OCX Get Rating) and Lucira Health (NASDAQ:LHDX Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, ...
Frequently Asked Questions
Frequently Asked Questions
What is Oncocyte Corp share price today?
Can Indians buy Oncocyte Corp shares?
How can I buy Oncocyte Corp shares from India?
Can Fractional shares of Oncocyte Corp be purchased?
What are the documents required to start investing in Oncocyte Corp stocks?
What is today’s traded volume of Oncocyte Corp?
What is today’s market capitalisation of Oncocyte Corp?
What is the 52-Week High and Low Range of Oncocyte Corp?
What percentage is Oncocyte Corp down from its 52-Week High?
What percentage is Oncocyte Corp up from its 52-Week Low?
Current Price
$2.16
$-0.03
(-1.37%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.